NCT07142707RecruitingPhase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
A Randomized, Double-blind, Placebo-controlled First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of MBX 4291 in Adult Participants With Obesity
Source: ClinicalTrials.gov · Last updated 9 Jun 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the safety and tolerability of single and multiple subcutaneous (SC) doses of MBX 4291 in adults with obesity.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 124 (estimated)
- First submitted
- 4 Aug 2025
- Start date
- 3 Sept 2025
- Primary completion date
- 30 Oct 2026
- Lead sponsor
- MBX Biosciences
- Diseases
- Obesity
- NCT number
- NCT07142707
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 124
- From 3 Sept 2025 to the primary completion date, 30 Oct 2026
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of, or currently active, significant illness or medical disorders that in the opinion of the investigator may preclude participants from participating in the study.
- History of currently active pancreatitis, type I and type II diabetes.
- A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Other
- Secondary causes of obesity, including but not limited to hypothalamic, monogenic, syndromic, or endocrine causes.
Who the study is looking for
- Age of \>18 to ≤65 years at the time of signing the informed consent.
- Has a BMI of ≥30 to \<50 kg/m2 at screening and baseline.
- Weight-stable, i.e., no more than ±5% change in body weight for at least 3 months prior to screening and between screening and baseline.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Doral | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Kansas City | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Knoxville | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Lexington | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.